
Sign up to save your podcasts
Or


- Pathology response measured by the CRS is associated with disease-free and overall survival in patients with stage IIIC/IV treated with neoadjuvant chemotherapy irrespective of the number of cycles.
By BMJ Group5
2323 ratings
- Pathology response measured by the CRS is associated with disease-free and overall survival in patients with stage IIIC/IV treated with neoadjuvant chemotherapy irrespective of the number of cycles.

39 Listeners

51 Listeners

5 Listeners

8 Listeners

5 Listeners

3 Listeners

2 Listeners

4 Listeners

9 Listeners

38 Listeners

14 Listeners

1 Listeners

51 Listeners

0 Listeners

6 Listeners

14 Listeners

3 Listeners

3 Listeners

26 Listeners